Arcus Biosciences (RCUS) Stock Forecast & Price Target

Compare

521 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RCUS Analyst Ratings

Strong Buy

10 Buy

2 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Arcus

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RCUS Stock 12 Month Forecast

Average Price Target

$29.22

▲(49.39% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Arcus Biosciences in the last 3 months. The average price target is $29.22 with a high forecast of $56.00 and a low forecast of $14.00. The average price target represents a 49.39% change from the last price of $19.56.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","57":"$57","18.75":"$18.75","31.5":"$31.5","44.25":"$44.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,18.75,31.5,44.25,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.48,16.75076923076923,20.021538461538462,23.29230769230769,26.56307692307692,29.833846153846153,33.104615384615386,36.37538461538462,39.646153846153844,42.91692307692307,46.1876923076923,49.458461538461535,52.72923076923077,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.48,14.69076923076923,15.901538461538461,17.11230769230769,18.323076923076922,19.533846153846152,20.744615384615386,21.955384615384617,23.166153846153847,24.376923076923077,25.587692307692308,26.798461538461538,28.00923076923077,{"y":29.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.48,13.52,13.56,13.6,13.64,13.68,13.72,13.76,13.8,13.84,13.88,13.92,13.96,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.42,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.89,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$56.00

Average Price Target$29.22

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Salveen Richter

Goldman Sachs

$14→$16

Hold

-18.20%

Downside

Reiterated

10/30/25

Goldman Sachs Sticks to Its Hold Rating for Arcus Biosciences (RCUS)

Terence Flynn

Morgan Stanley

$23

Buy

17.59%

Upside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: MiMedx Group (NASDAQ: MDXG), TransMedics Group (NASDAQ: TMDX) and Arcus Biosciences (NYSE: RCUS)Arcus Biosciences Inc Overweight, PT remains at 23.00.

Yigal Nochomovitz

Citi

$54→$56

Buy

186.30%

Upside

Reiterated

10/30/25

Arcus Biosciences price target raised to $56 from $54 at CitiArcus Biosciences price target raised to $56 from $54 at Citi

Emily Bodnar

H.C. Wainwright

$24→$28

Buy

43.15%

Upside

Reiterated

10/29/25

Arcus Biosciences price target raised to $28 from $24 at H.C. WainwrightArcus Biosciences price target raised to $28 from $24 at H.C. Wainwright

Robert Driscoll

Wedbush

$33→$35

Buy

78.94%

Upside

Reiterated

10/29/25

Wedbush Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

10/29/25

Truist Financial Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

Peter Lawson

Barclays

$14

Buy

-28.43%

Downside

Reiterated

10/28/25

Arcus Biosciences (RCUS) Receives a Buy from Barclays

Jason Zemansky

Bank of America Securities

$16→$17

Hold

-13.09%

Downside

Reiterated

10/20/25

Arcus Biosciences (RCUS) Gets a Hold from Bank of America SecuritiesWith the update modestly de-risking, our PO moves to $17 from $16. Absent more clinical certainty, though, reiterate Neutral.

Eva Fortea Verdejo

Wells Fargo

$25→$29

Buy

48.26%

Upside

Reiterated

10/20/25

Wells Fargo Keeps Their Buy Rating on Arcus Biosciences (RCUS)

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

10/08/25

Evercore ISI Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

Li Watsek

Cantor Fitzgerald

―

Buy

―

Reiterated

10/08/25

Arcus Biosciences (RCUS) Gets a Buy from Cantor FitzgeraldCantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Arcus Biosciences (NYSE: RCUS).

Salim Syed

Mizuho Securities

$42→$45

Buy

130.06%

Upside

Reiterated

08/18/25

Mizuho Securities Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)RCUS (OP, increasing PT to $45 from $42): Investor focus should start pivoting more heavily to cas. We increase our price target to $45 from $42, due primarily to casdatifan (HIF-2a inccRCC).

Daina Graybosch

Leerink Partners

$46→$52

Buy

165.85%

Upside

Reiterated

08/07/25

Leerink Partners Sticks to Their Buy Rating for Arcus Biosciences (RCUS)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Salveen Richter

Goldman Sachs

$14→$16

Hold

-18.20%

Downside

Reiterated

10/30/25

Goldman Sachs Sticks to Its Hold Rating for Arcus Biosciences (RCUS)

Terence Flynn

Morgan Stanley

$23

Buy

17.59%

Upside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: MiMedx Group (NASDAQ: MDXG), TransMedics Group (NASDAQ: TMDX) and Arcus Biosciences (NYSE: RCUS)Arcus Biosciences Inc Overweight, PT remains at 23.00.

Yigal Nochomovitz

Citi

$54→$56

Buy

186.30%

Upside

Reiterated

10/30/25

Arcus Biosciences price target raised to $56 from $54 at CitiArcus Biosciences price target raised to $56 from $54 at Citi

Emily Bodnar

H.C. Wainwright

$24→$28

Buy

43.15%

Upside

Reiterated

10/29/25

Arcus Biosciences price target raised to $28 from $24 at H.C. WainwrightArcus Biosciences price target raised to $28 from $24 at H.C. Wainwright

Robert Driscoll

Wedbush

$33→$35

Buy

78.94%

Upside

Reiterated

10/29/25

Wedbush Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

10/29/25

Truist Financial Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

Peter Lawson

Barclays

$14

Buy

-28.43%

Downside

Reiterated

10/28/25

Arcus Biosciences (RCUS) Receives a Buy from Barclays

Jason Zemansky

Bank of America Securities

$16→$17

Hold

-13.09%

Downside

Reiterated

10/20/25

Arcus Biosciences (RCUS) Gets a Hold from Bank of America SecuritiesWith the update modestly de-risking, our PO moves to $17 from $16. Absent more clinical certainty, though, reiterate Neutral.

Eva Fortea Verdejo

Wells Fargo

$25→$29

Buy

48.26%

Upside

Reiterated

10/20/25

Wells Fargo Keeps Their Buy Rating on Arcus Biosciences (RCUS)

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

10/08/25

Evercore ISI Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

Li Watsek

Cantor Fitzgerald

―

Buy

―

Reiterated

10/08/25

Arcus Biosciences (RCUS) Gets a Buy from Cantor FitzgeraldCantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Arcus Biosciences (NYSE: RCUS).

Salim Syed

Mizuho Securities

$42→$45

Buy

130.06%

Upside

Reiterated

08/18/25

Daina Graybosch

Leerink Partners

$46→$52

Buy

165.85%

Upside

Reiterated

08/07/25

Leerink Partners Sticks to Their Buy Rating for Arcus Biosciences (RCUS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcus Biosciences

1 Month

xxx

Success Rate

8/14 ratings generated profit

Average Return

+5.69%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +5.69% per trade.

3 Months

xxx

Success Rate

12/21 ratings generated profit

Average Return

+6.30%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +6.30% per trade.

1 Year

Peter LawsonBarclays

Success Rate

15/27 ratings generated profit

Average Return

+26.09%

reiterated a buy rating 11 days ago

Copying Peter Lawson's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +26.09% per trade.

2 Years

xxx

Success Rate

19/27 ratings generated profit

Average Return

+32.44%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.37% of your transactions generating a profit, with an average return of +32.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RCUS Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RCUS has received 30 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. RCUS average Analyst price target in the past 3 months is 29.22.

Each month's total comprises the sum of three months' worth of ratings.

RCUS Financial Forecast

RCUS Earnings Forecast

Next quarter’s earnings estimate for RCUS is -$1.17 with a range of -$1.32 to -$1.00. The previous quarter’s EPS was -$1.27. RCUS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year RCUS has Preformed in-line its overall industry.

RCUS Sales Forecast

Next quarter’s sales forecast for RCUS is $26.25M with a range of $16.00M to $40.00M. The previous quarter’s sales results were $26.00M. RCUS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year RCUS has Preformed in-line its overall industry.

RCUS Stock Forecast FAQ

What is RCUS’s average 12-month price target, according to analysts?

Based on analyst ratings, Arcus Biosciences Inc’s 12-month average price target is 29.22.

What is RCUS’s upside potential, based on the analysts’ average price target?

Arcus Biosciences Inc has 49.39% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RCUS a Buy, Sell or Hold?

Arcus Biosciences Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.

What is Arcus Biosciences Inc’s price target?

The average price target for Arcus Biosciences Inc is 29.22. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $56.00 ,the lowest forecast is $14.00. The average price target represents 49.39% Increase from the current price of $19.56.

What do analysts say about Arcus Biosciences Inc?

Arcus Biosciences Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of RCUS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Arcus Biosciences (RCUS) Stock Forecast & Price Target

RCUS Analyst Ratings

RCUS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Arcus Biosciences

RCUS Analyst Recommendation Trends

RCUS Financial Forecast

RCUS Earnings Forecast

RCUS Sales Forecast

RCUS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts